Hong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Rises Over 5% After Expanding Partnership with AFT for Commercialization of BRIMOCHOL™ PF in Singapore

Stock News

Jan 27

ZHAOKE OPHTH-B (06622) surged more than 5%, with a gain of 4.56% at the time of writing to HK$3.44, on a trading volume of HK$1.707 million. On January 26, the company announced it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore. The company has also established a strategic partnership with Chibret International, a prominent Asian ophthalmic company, to commercialize the product in Vietnam. ZHAOKE OPHTH-B has granted AFT and Chibret exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets. Through these agreements, AFT and Chibret become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion. BRIMOCHOL™ PF is a potential treatment for correcting presbyopia-induced loss of near vision and is a core asset licensed by the company from its partner Tenpoint Therapeutics, Ltd. (Tenpoint).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1192536740"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192536740\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192536740?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 11:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192536740","market":"nz","top_or_hot":-1,"title":"Hong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Rises Over 5% After Expanding Partnership with AFT for Commercialization of BRIMOCHOL™ PF in Singapore","media":"Stock News","content":"<p>ZHAOKE OPHTH-B (06622) surged more than 5%, with a gain of 4.56% at the time of writing to HK$3.44, on a trading volume of HK$1.707 million.\nOn January 26, the company announced it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore.\nThe company has also established a strategic partnership with Chibret International, a prominent Asian ophthalmic company, to commercialize the product in Vietnam.\nZHAOKE OPHTH-B has granted AFT and Chibret exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets.\nThrough these agreements, AFT and Chibret become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion.\nBRIMOCHOL™ PF is a potential treatment for correcting presbyopia-induced loss of near vision and is a core asset licensed by the company from its partner Tenpoint Therapeutics, Ltd. (Tenpoint).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Rises Over 5% After Expanding Partnership with AFT for Commercialization of BRIMOCHOL™ PF in Singapore</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | ZHAOKE OPHTH-B (06622) Rises Over 5% After Expanding Partnership with AFT for Commercialization of BRIMOCHOL™ PF in Singapore\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 11:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZHAOKE OPHTH-B (06622) surged more than 5%, with a gain of 4.56% at the time of writing to HK$3.44, on a trading volume of HK$1.707 million.\nOn January 26, the company announced it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore.\nThe company has also established a strategic partnership with Chibret International, a prominent Asian ophthalmic company, to commercialize the product in Vietnam.\nZHAOKE OPHTH-B has granted AFT and Chibret exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets.\nThrough these agreements, AFT and Chibret become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion.\nBRIMOCHOL™ PF is a potential treatment for correcting presbyopia-induced loss of near vision and is a core asset licensed by the company from its partner Tenpoint Therapeutics, Ltd. (Tenpoint).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AFT","symbol_name":"Apollo Senior Floating Rate Fund","start_time":0,"source_url":"","article_id":"1192536740","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192536740","pubTimestamp":1769483482,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ZHAOKE OPHTH-B (06622) surged more than 5%, with a gain of 4.56% at the time of writing to HK$3.44, on a trading volume of HK$1.707 million. On January 26, the company announced it has expanded its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AFT":"Apollo Senior Floating Rate Fund","BK1583":"高瓴概念","BK1191":"制药","06622":"兆科眼科-B","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"港股动向|兆科眼科-B(06622)与AFT扩大合作伙伴关系商业化BRIMOCHOL后涨超5%™新加坡的PF","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFT":1,"06622":1},"content_text":"ZHAOKE OPHTH-B (06622) surged more than 5%, with a gain of 4.56% at the time of writing to HK$3.44, on a trading volume of HK$1.707 million.\nOn January 26, the company announced it has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL™ PF in Singapore.\nThe company has also established a strategic partnership with Chibret International, a prominent Asian ophthalmic company, to commercialize the product in Vietnam.\nZHAOKE OPHTH-B has granted AFT and Chibret exclusive distribution rights for Singapore and Vietnam, respectively, which include the rights to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in the relevant markets.\nThrough these agreements, AFT and Chibret become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, underscoring the company's firm commitment to global expansion.\nBRIMOCHOL™ PF is a potential treatment for correcting presbyopia-induced loss of near vision and is a core asset licensed by the company from its partner Tenpoint Therapeutics, Ltd. (Tenpoint).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}